Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2025)

Innate Pharma has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $3.0 million in Q2 2025.

• For the quarter ending Q2 2025, Non-Current Deffered Revenue fell 32.89% year-over-year to $3.0 million; the trailing twelve-month figure through Jun 2025 stood at $3.0 million (down 32.89% YoY), and the FY2024 full-year result was $3.0 million, down 39.24% from the prior year.
• Non-Current Deffered Revenue for Q2 2025 stood at $3.0 million, down from $3.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $33.2 million in Q2 2021, with the low at $3.0 million in Q2 2025.
• Historically, Non-Current Deffered Revenue has averaged $11.2 million across 5 years, with a median of $6.5 million in 2023.
• The largest YoY upside for Non-Current Deffered Revenue was 25.37% in 2021 against a maximum downside of 99.84% in 2021.
• Innate Pharma's Non-Current Deffered Revenue stood at $29.1 million in 2021, then tumbled by 72.2% to $8.1 million in 2022, then tumbled by 38.52% to $5.0 million in 2023, then sank by 39.24% to $3.0 million in 2024, then declined by 1.46% to $3.0 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $3.0 million (Q2 2025), $3.0 million (Q4 2024), and $4.4 million (Q2 2024), per Business Quant data.